FOCUS on Reversal of Tau Pathology. In a January Communications Biology paper, Eric McGregor and coworkers showed that adiponectin receptor activation with the small molecule agonist,
FOCUS on Bioactive Natural Products. In a February Nature Communications paper, Wang and coworkers showed that a sesquiterpenoid found abundantly in ginger, known as furanodienone, alleviated
FOCUS on New Drug Approvals. Last Friday the FDA granted full approval of Deciphera’s Romvimza™ (Vimseltinib) for the treatment of symptomatic tenosynovial giant cell tumor (TGCT)
FOCUS on New Drug Approvals. Yesterday the FDA approved SpringWorks Therapeutics‘ Mirdametinib (PD-325901) for the treatment of patients with neurofibromatosis type 1 with symptomatic plexiform neurofibromas
Focus on drug discovery failure. Development of Risvodetinib for Parkinson’s disease was halted following disappointing Phase II results. The drug, which is a potent, brain-penetrant c-Abl
Focus on New Drug Approvals. The FDA approved Vertex Pharmaceutical’s Suzetrigine (VX-548) for the treatment of moderate to severe acute pain in adults. Suzetrigine is a
BOGO
